A prodrug of cysteine, L-2-oxothiazolidine-4-carboxylic acid, regulates vascular permeability by reducing vascular endothelial growth factor expression in asthma

Molecular Pharmacology

Volumn 68, Issue 5, 2005, Pages 1281-1290

  Lee, Kyung Sun ^a   Hee, Sun Park ^a   Seoung, Ju Park ^a   So, Ri Kim ^a   Kyung, Hoon Min ^a   Sun, Mi Jin ^a   Park, Kwang Hyun ^a   Kim, Uh Hyun ^a   Chan, Young Kim ^a   Yong, Chul Lee ^a  

^a Chonbuk National University Medical School   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXO 4 THIAZOLIDINECARBOXYLIC ACID; ALLERGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NUCLEAR PROTEIN; OVALBUMIN; REACTIVE OXYGEN METABOLITE; VASCULOTROPIN;

AIRWAY; ALLERGIC REACTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTHMA; BLOOD VESSEL PERMEABILITY; CLINICAL FEATURE; CONTROLLED STUDY; EXTRAVASATION; FEMALE; IMMUNE RESPONSE; INFLAMMATORY CELL; LUNG PARENCHYMA; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION; TREATMENT OUTCOME;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ASTHMA; CAPILLARY PERMEABILITY; FEMALE; MICE; MICE, INBRED BALB C; OVALBUMIN; PHOSPHORYLATION; PRODRUGS; PYRROLIDONECARBOXYLIC ACID; REACTIVE OXYGEN SPECIES; THIAZOLES; THIAZOLIDINES; THIOCTIC ACID; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 27544492881     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.105.016055     Document Type: Article

References (50)

1. Ametov AS, Barinov A, Dyck PJ, Hermann R, Kozlova N, Litchy WJ, Low PA, Nehrdich D, Novosadova M, O'Brien PC, et al. (2003) The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care 26:770-776.
2. Asti C, Melillo G, Caselli GF, Daffonchio L, Hernandez A, Clavenna G, and Omini C (1995) Effectiveness of carbocysteine lysine salt monohydrate on models of airway inflammation and hyperresponsiveness. Pharmacol Res 31:387-392.
3. Blesa S, Cortijo J, Martinez-Losa M, Mata M, Seda E, Santangelo F, and Morcillo EJ (2002) Effectiveness of oral N-acetylcysteine in a rat experimental model of asthma. Pharmacol Res 45:135-140.
4. Bousquet J, Jeffery PK, Busse WW, Johnson M, and Vignola AM (2000) Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 161:1720-1745.
5. Cao X and Phillis JW (1995) The free radical scavenger, alpha-lipoic acid, protects against cerebral ischemia-reperfusion injury in gerbils. Free Radic Res 23:365-370.
6. Chandel NS, McClintock DS, Feliciano CE, Wood TM, Melendez JA, Rodriguez AM, and Schumacker PT (2000) Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1α during hypoxia. J Biol Chem 275:25130-25138.
7. Cho YS, Lee J, Lee TH, Lee EY, Lee KU, Park JY, and Moon HB (2004) alpha-Lipoic acid inhibits airway inflammation and hyperresponsiveness in a mouse model of asthma. J Allergy Clin Immunol 114:429-435.
8. Dvorak AM, Tepper RI, Weller PF, Morgan ES, Estrella P, Monahan-Earley RA, and Galli SJ (1994) Piecemeal degranulation of mast cells in the inflammatory eyelid lesions of interleukin-4 transgenic mice. Evidence of mast cell histamine release in vivo by diamine oxidase-gold enzyme-affinity ultrastructural cytochemistry. Blood 83:3600-3612.
9. Dvorak HF, Brown LF, Detmar M, and Dvorak AM (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability and angiogenesis. Am J Pathol 146:1029-1039.
10. Dworski R (2000) Oxidant stress in asthma. Thorax 55:S51-S53.
11. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, et al. (2001) C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107:43-54.
12. Eum SY, Maghni K, Hamid Q, Campbell H, Eidelman DH, and Martin JG (2003) Involvement of the cysteinyl-leukotrienes in allergen-induced airway eosinophilia and hyperresponsiveness in the mouse. Am J Respir Cell Mol Biol 28:25-32.
13. Foster WM, Langenback EG, and Bergofsky EH (1982) Lung mucociliary function in man: interdependence of bronchial and tracheal mucus transport velocities with lung clearance in bronchial asthma and healthy subjects. Ann Occup Hyg 26:227-244.
14. Haddad JJ and Land SC (2001) A non-hypoxia, ROS-sensitive pathway mediates TNF-alpha-dependent regulation of HIF-1alpha. FEBS Lett 505:269-274.
15. Han MK, Kim SJ, Park YR, Shin YM, Park HJ, Park KJ, Park KH, Kim HK, Jang SI, An NH, et al. (2002) Antidiabetic effect of a prodrug of cysteine, L-2-oxothiazolidine-4-carboxylic acid, through CD38 dimerization and internalization. J Biol Chem 277:5315-5321.
16. Henricks PA and Nijkamp FP (2001) Reactive oxygen species as mediators in asthma. Pulm Pharmacol Ther 14:409-420.
17. Hoshino M, Nakamura Y, and Hamid QA (2001) Gene expression of vascular endothelial growth factor and its receptors and angiogenesis in bronchial asthma. J Allergy Clin Immunol 107:1034-1038.
18. 2 sensing. Science (Wash DC) 292:464-468.
19. 2-regulated prolyl hydroxylation. Science (Wash DC) 292:468-472.
20. Jung YJ, Isaacs JS, Lee S, Trepel J, and Neckers L (2003) IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J 17:2115-2117.
21. Kaelin WG Jr (2002) How oxygen makes its presence felt. Genes Dev 16:1441-1445.
22. Kuroki M, Voest EE, Amano S, Beerepoot LV, Takashima S, Tolentino M, Kim RY, Rohan RM, Colby KA, Yeo KT, et al. (1996) Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Investig 98:1667-1675.
23. Kwak YG, Song CH, Yi HK, Hwang PH, Kim JS, Lee KS, and Lee YC (2003) Involvement of PTEN in airway hyperresponsiveness and inflammation in bronchial asthma. J Clin Invest 111:1083-1092.
24. Laughner E, Taghavi P, Chiles K, Mahon PC, and Semenza GL (2001) HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21:3995-4004.
25. Lee CG, Link H, Baluk P, Homer RJ, Chapoval S, Bhandari V, Kang MJ, Cohn L, Kim YK, McDonald DM, et al. (2004a) Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. Nat Med 10:1095-1103.
26. Lee M, You HJ, Cho SH, Woo CH, Yoo MH, Joe EH, and Kim JH (2002a) Implication of the small GTPase Racl in the generation of reactive oxygen species in response to β-amyloid in C6 astrolgioma cells. Biochem J 366:937-943.
27. Lee YC, Kwak YG, and Song CH (2002b) Contribution of vascular endothelial growth factor to airway hyper-responsiveness and inflammation in a murine model of toluene diisocyanate-induced asthma. J Immunol 168:3595-3600.
28. Lee YC and Lee HK (2001) Vascular endothelial growth factor in patients with acute asthma. J Allergy Clin Immunol 107:1106.
29. Lee YC, Lee KS, Park SJ, Park HS, Lim JS, Park KH, Im MJ, Choi IW, Lee HK, and Kim UH (2004b) Blockade of airway hyperresponsiveness and inflammation in a murine model of asthma by a prodrug of cysteine, L-2-oxothiazolidine-4- carboxylic acid. FASEB J 18:1917-1919.
30. Li YM, Zhou BP, Deng J, Pan Y, Hay N, and Hung M (2005) A hypoxia independent hypoxia-inducible factor-1 activation pathway induced by phosphatidylinositol-3 kinase/Akt in HER2 overexpressing cells. Cancer Res 65:3257-3263.
31. Lukashev D, Caldwell C, Ohta A, Chen P, and Sitkovsky M (2001) Differential regulation of two alternatively spliced isoforms of hypoxia-inducible factor-1 alpha in activated T lymphocytes. J Biol Chem 276:48754-48763.
32. MacNee W (2001) Oxidative stress and lung inflammation in airways disease. Eur J Pharmacol 429:195-207.
33. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, and Ratcliffe PJ (1999) The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature (Lond) 399:271-275.
34. Mesina JE, Page RH, Hetzel FW, and Chopp M (1989) Administration of L-2-oxothiazolidine-4-carboxylate increases glutathione levels in rat brain. Brain Res 478:181-183.
35. Mottet D, Dumont V, Deccache Y, Demazy C, Ninane N, Raes M, and Michiels C (2003) Regulation of hypoxia-inducible factor-1α protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3β pathway in HepG2 cells. J Biol Chem 278:31277-31285.
36. Oiry J, Puy JY, Mialocq P, Clayette P, Fretier P, Jaccard P, Dereuddre-Bosquet N, Dormont D, and Imbach JL (1999) Synthesis and in vitro anti-HIV activity in human monocyte-derived macrophages of 2-oxothiazolidine- 4(R)-carboxylic acid derivatives. J Med Chem 42:4733-4740.
37. Persson CG (1996) Epithelial cells: barrier functions and shedding restitution mechanisms. Am J Respir Crit Care Med 153:S9-S10.
38. Porta P, Aebi S, Summer K, and Lauterburg BH (1991) L-2-Oxothiazolidine- 4-carboxylic acid, a cysteine prodrug: pharmacokinetics and effects on thiols in plasma and lymphocytes in human. J Pharmacol Exp Ther 257:331-334.
39. Rahman I, Morrison D, Donaldson K, and MacNee W (1996) Systemic oxidative stress in asthma, COPD and smokers. Am J Respir Crit Care Med 154:1055-1060.
40. 2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 15:551-578.
41. Semenza GL (2001) Hypoxia-inducible factor 1: control of oxygen homeostasis in health and disease. Pediatr Res 49:614-617.
42. 2 for platelet-derived growth factor signal transduction. Science (Wash DC) 270:296-299.
43. Takeda K, Hamelmann E, Joetham A, Shultz LD, Larsen GL, Irvin CG, and Gelfand EW (1997) Development of eosinophilic airway inflammation and airway hyperresponsiveness in mast cell-deficient mice. J Exp Med 186:449-454.
44. Tournoy KG, Kips JC, Schou C, and Pauwels RA (2000) Airway eosinophilia is not a requirement for allergen-induced airway hyperresponsiveness. Clin Exp Allergy 30:79-85.
45. Treins C, Giogetti-Peraldi S, Murdaca J, Semenza GL, and Van Obberghen E (2002) Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem 277:27975-27981.
46. Van de Graaf EA, Out TA, Roos CM, and Jansen HM (1991) Respiratory membrane permeability and bronchial hyperreactivity in patients with stable asthma. Effects of therapy with inhaled steroids. Am Rev Respir Dis 143:362-368.
47. Vita JA, Frei B, Holbrook M, Gokce N, Leaf C, and Keaney JF Jr (1998) L-2-Oxothiazolidine-4-carboxylic acid reverses endothelial dysfunction in patients with coronary artery disease. J Clin Investig 101:1408-1414.
48. Wang GL and Semenza GL (1995) Purification and characterization of hypoxiainducible factor 1. J Biol Chem 270:1230-1237.
49. Williamson JM and Meister A (1981) Stimulation of hepatic glutathione formation by administration of L-2-oxothiazolidine-4-carboxylate, a 5-oxo-L-prolinase substrate. Proc Natl Acad Sci USA 78:936-939.
50. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, and Semenza GL (2000) Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/ AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60:1541-1545.